Media.Player

Multi-Target Inhibitors for Pain Treatment

Technology Benefits

Targeting two enzymes with a single chemical structure

Technology Application

Pharmaceutical treatment for pain Research tool

Detailed Technology Description

Soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) regulate inflammation, pain and other biological processes relevant to human health. Their biological activities are mediated by their substrates epoxyeicosatrienoic acid (EET) and arachidonoyl ethanolamide (AEA), respectively, and are essential components of eicosanoid and endocannabinoid signaling, respectively. These signaling pathways are known to modulate a number of disease states, including chronic pain, hypertension and cancer, and thus, these two enzymes are promising clinical targets. Despite substantial promising pre-clinical data for both sEH and FAAH inhibitors, none of the clinical trials to date have demonstrated efficacy for either target. One approach to overcoming this obstacle is to target two or more parallel pathways involved in the same disease. To harness this synergy while simplifying pharmacokinetics, researchers at the University of California, Davis have developed dual inhibitors that concurrently inhibit these two targets. These dual inhibitors may be applied as powerful therapeutics and are useful experimental tools for identifying other indications where sEH/FAAH synergy may be used therapeutically.

Others

Additional Technologies by these Inventors

• Improved Dioxin Detection and Measurement
• Recombinant Neurotoxin: A More Effective Insecticide
• Antibodies: Urea Herbicide Pabs
• Antibodies: Triazine Herbicide Pabs
• Antibodies: Bacillus Delta Endotoxin PAbs
• Antibodies: Bromacil Herbicide PAbs
• Novel and Specific Inhibitors of p21
• Beneficial Effects of Novel Inhibitors of Soluble Epoxide Hydrolase as Adjuvant Treatment for Cardiac Cell-Based Therapy
• Novel Neuropathy Treatment Using Soluble Epoxide Inhibitors
• Detection System for Small Molecules
• Methods and Compositions of Treating Diabetic Nephropathy and Insulin Resistance
• Method of Preventing Bone Loss and Periodontal Disease
• A New Pharmaceutical Therapy Target for Depression and Other Central Nervous System Diseases
• Antibodies for Pseudomonas (P.) aeruginosa
• Chemical Synthesis of Lipid Mediator 22-HDoHE and Structural Analogs
• Soluble Epoxide Hydrolase-Conditioned Stem Cells for Cardiac Cell-Based Therapy
• PTUPB Compound Potentiates Cisplatin-Based-First Line Therapies with No Additional Toxicity
• Small Molecule sEH Inhibitors to Treat Alpha-Synuclein Neurodegenerative Disorders
• Bioavailable Dual sEH/PDE4 Inhibitor for Inflammatory Pain

Tech ID/UC Case

27192/2016-505-0

Related Cases

2016-505-0

*Abstract

Researchers at the University of California, Davis have developed compounds that concurrently inhibit Soluble Epoxide Hydrolase (sEH) and Fatty Acid Amide Hydrolase (FAAH as therapeutics for treating pain. sEH and FAAH inhibition have been independently developed as pharmaceutical targets for treating inflammatory and neuropathic pain but concurrent inhibition of these two targets is synergistic and combining of both targets into a single therapeutic approach may provide better pain relief for patients.

*Principal Investigator

Name: Bruce Hammock

Department:

Name: Sean Kodani

Department:

Country/Region

USA